Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Affymetrix SNP-array data for fetal tissue from recurrent pregnancy loss patients

ABSTRACT: Background. Recurrent pregnancy loss (RPL) is often associated with genetic factors. This study investigates chromosomal abnormalities in RPL by analyzing copy number variations (CNVs) and single nucleotide variants (SNVs). Methods. We conducted a retrospective analysis of 400 RPL patients, with 393 successfully analyzed using CNV-seq and SNP-array after excluding maternal cell contamination (MCC). Additionally, 16 families with normal results underwent whole exome sequencing (WES). Results. Among the patients, 187 (47.6%) showed normal results, while 206 (52.4%) exhibited abnormalities, including 152 aneuploidies (73.8%), 37 CNVs (18.0%), and 17 triploidies (8.3%). Statistical analysis revealed a significant increase in chromosomal abnormalities with advancing maternal age, but no significant differences in rates were observed before 24 weeks of pregnancy in patients with two or more miscarriages. We identified 28 pathogenic (P) / likely pathogenic (LP) CNVs and 6 P / LP SNVs, implicating 808 morbid genes. Enrichment analysis and protein-protein interaction (PPI) network construction revealed 69 key genes in critical pathways, with IL6, TNF, and ACTB as hub genes. Discussion. These findings contribute to establishing genetic markers for RPL screening in the Chinese population, enhancing our understanding of miscarriage etiology and facilitating prenatal diagnosis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE310872 | GEO | 2025/11/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

EV-microRNA Signatures in Pregnant Women with Idiopathic Recurrent Pregnancy Loss: Deciphering MicroRNAome Pathway Networks at Feto-Maternal Interface

Project description:Despite extensive research in the past decade, the exact pathogenesis of recurrent pregnancy loss (RPL) remains unknown. At the time of pregnancy, human placenta releases microRNAs (miRNAs) enclosed in extracellular vesicles (EVs), which enter into maternal circulation and play an important role at feto-maternal interface to sustain a successful pregnancy. Aberrant expression of these miRNAs often results in adverse pregnancy complications. Therefore, studying the expression of these EV-miRNAs in maternal circulation could provide insights into the pathogenesis of RPL. miRNA sequencing revealed 66 (44 known and 22 novel) significantly DE miRNAs between RPL and healthy pregnant women.

2025-05-07 | GSE296460 | GEO

Comparative proteomics analysis of decidua tissues in early recurrent pregnancy loss

Project description:The project aimed to determine proteomics changes in decidua from patients suffering from unexplained early recurrent pregnancy loss (RPL) compared to women undergoing elective abortions. Comparative proteomics analysis by label-free data-independent LC-MS/MS was performed on fresh frozen decidua tissues from 19 RPL patients and 10 controls. Samples from EPL patients were preselected to include only patients with 2 or more recurrent pregnancy losses (RPL), no previous live birth, gestational week from 6-10 weeks and excluded fetal chromosomal abnormalities. Control samples were from women without history of previous miscarriage, ectopic pregnancy or preterm delivery, with at least one live born child, at 6-10 gestational weeks and without fetal chromosomal abnormalities. Patients and controls had no significant differences regarding age (Median age RPL = 30; Median age Controls = 34; Mann–Whitney U-test p = 0.082). The mean gestational weak (GW) was 7.9±1.0 weeks in the RPL group and 8.3±1.2 weeks in the control group, without statistically significant difference between groups (Median GW RPL = 8; Median GW Controls = 8; Mann–Whitney U-test p = 0.361).

2024-06-12 | PXD048340 | Pride

Comparative proteomics analysis of chorionic villi in recurrent pregnancy loss

Project description:The project aimed to determine proteomics changes in chorionic villi from patients suffering from unexplained early recurrent pregnancy loss (RPL) compared to women undergoing elective abortions. Comparative proteomics analysis by label-free data-independent LC-MS/MS was performed on fresh frozen chorionic villi from 13 RPL patients and 10 controls. Samples from EPL patients were preselected to include only patients with 2 or more recurrent pregnancy losses (RPL), no previous live birth, gestational week from 6-10 weeks and excluded fetal chromosomal abnormalities. Control samples were from women without history of previous miscarriage, ectopic pregnancy or preterm delivery, with at least one live born child, at 6-10 gestational weeks and without fetal chromosomal abnormalities. Patients and controls were between 24-44 years with no significant differences among groups regarding age (Median age RPL = 29; Median age Controls = 34; Mann–Whitney U-test p = 0.078). The mean gestational weak (GW) was 7.9±0.8 weeks in the RPL group and 8.3±1.2 weeks in the control group, without statistically significant difference between groups (Median GW RPL = 8; Median GW Controls = 8; Mann–Whitney U-test p = 0.484).

2024-08-27 | PXD048344 | Pride

CCR8+ decidual regulatory T cells maintain maternal-fetal immune tolerance during early pregnancy

Project description:Regulatory T cells (Tregs) play crucial roles in maintaining maternal immune tolerance to the semi-allogeneic fetus during pregnancy, but Treg population heterogeneity and tissue-specific functions in human decidua remain largely unknown. Here, we conducted single-cell transcriptomic and T cell receptor sequencing of CD4+ T cells from first-trimester decidua and matched peripheral blood of pregnant women. These analyses identified a highly activated, immunosuppressive CCR8+ Treg subset specifically enriched in decidua (dTregs). CCR8+ dTregs are decreased in recurrent pregnancy loss (RPL) patients and abortion-prone model mice. Depletion of this subset with anti-CCR8 antibodies alters the decidual immune profile, increasing susceptibility to fetal loss. The CCR8 ligand, CCL1, is mainly produced by decidual CD49a+ NK cells and is also significantly decreased in RPL patients. By characterizing the landscape of dTregs in human early pregnancy, we identified CCR8+ dTregs as crucial for maintaining maternal-fetal tolerance, suggesting new potential strategies for RPL diagnosis and therapy.

2025-04-15 | GSE252187 | GEO

Machine learning–driven decoding of maternal immune signatures in repeated pregnancy loss

Project description:Repeated pregnancy loss (RPL) is a multifactorial condition with incompletely understood immunological mechanisms, particularly the immune disruptions contributing to RPL independent of fetal aneuploidy. To dissect this immune dysregulation, we performed single-cell RNA sequencing of decidual tissues from RPL patients and controls. Our analysis revealed that in RPL, fetal immune cells increased while fetal trophoblasts were reduced, and notably, RPL immune cells displayed transcriptional signatures resembling acute transplant rejection. Using machine learning and foundation models, we identified broad T-cell–derived transcriptomic signatures that distinguish RPL immune cells. To prioritize these candidates, we integrated network analysis and assessed their potential for therapeutic reversal using drug response data. After this rigorous filtering, we then controlled for biological confounding factors, a process which robustly identified CXCR4 and JUN in maternal T cells as the key RPL-associated signatures. The drug response analysis also highlighted three specific compounds as candidates for repurposing. Together, our approach identifies critical maternal immune signatures in RPL and links them to potential therapeutic opportunities, thereby providing both mechanistic insights and new avenues for treatment.

2025-11-01 | GSE306259 | GEO

Maternal Circulating Exosomal miR-185-5p as Non-invasive Biomarker for the Prediction of Recurrent Pregnancy Loss.

Project description:Pregnancy losses usually happening suddenly and are irreversible, this study aims to find a predictive biomarker of the upcoming pregnancy loss. We collected serum exosomes from pregnant women prospectively from 6 to 8 weeks gestation and divided the patients into ongoing pregnancy (OP) group, sporadic pregnancy loss (SPL) group, and recurrent pregnancy loss (RPL) group according to the pregnancy progress and pregnancy history. Then we performed genome-wide miRNA expression profiling by small RNA sequencing to identify differences between patients who are going to lose pregnancy and who would not. The results showed there were 68 miRNAs differently expressed among three groups. When comparing RPL group with OP group, there was a set of 43 miRNAs differentially expressed including 25 miRNAs up-regulated in the RPL group and 18 miRNAs down-regulated. Compared SPL group with OP group, there was a set of 76 miRNAs differentially expressed including 24 miRNAs up-regulated in the SPL group and 52 miRNAs down-regulated. Moreover, we combined RPL group and SPL group into PL group, and then compared PL group with OP group, there were 81 miRNAs expressed differently while 60 were up-regulated and 21 were down-regulated. Our study found that there were significant differences in the expression levels of exosomal miRNAs in peripheral blood between patients who continued pregnancy and those who were about to miscarriage, suggesting that maternal peripheral blood exosomal miRNAs could be used as predictive molecular markers for miscarriage.

2024-04-25 | GSE200122 | GEO

A transcriptomic study of maternal thyroid adaptation to pregnancy in rats

Project description:To identify potential regulators of late pregnancy-dependent thyroid weight increase, thyroid gene expression profiles of non-pregnant (NP) and late pregnant (LP, day 18) rats was analyzed using the RNA-seq approach. Identifying global gene changes in the maternal thyroid in rats

2015-09-23 | E-GEOD-73307 | biostudies-arrayexpress

Chromosomal abnormalities of 564 miscarriages

Project description:Chromosomal abnormalities are important causes of miscarriages. To delinate the chromosomal abnormalities in miscarriages, 564 miscarriages were collected and analyzed using single nucleotide polymorphism (SNP) array. 336 (59.6%) miscarriages were with abnormal copy number variations (CNVs), including 325 (57.6%) miscarriages with pathogenic CNVs and 11 (2%) miscarriages with variations of unknown significance (VOUS). The remaining 228 (40.4%) miscarriages had no clinically relevant chromosomal variants.

2023-05-21 | GSE207887 | GEO

Genetic profiling of first-trimester chorionic villus samples using Affymetrix CytoScan 750K arrays

Project description:While chromosomal microarray analysis (CMA) is increasingly utilized in prenatal diagnosis, most research focuses on mid-to-late pregnancy amniotic fluid samples. Chorionic villus samples (CVS) from the first trimester possess distinct biological characteristics. To evaluate the efficacy of CMA in early pregnancy prenatal diagnosis, we performed a genomic analysis of CVS from high-risk pregnancies.We conducted a single-center cohort study of singleton pregnancies that underwent CVS between 11⁺⁰ and 13⁺⁶ weeks of gestation. Indications for testing included advanced maternal age, ultrasound-detected soft markers or structural anomalies, abnormal first-trimester serum screening, or adverse obstetric history. All villus samples were analyzed using CMA (Affymetrix CytoScan 750K arrays). Among the samples analyzed by CMA, 16.6% showed chromosomal abnormalities, with CNVs accounting for 58.9% of these cases. Compared with other indicators, the detection rate was significantly higher in the group with ultrasound abnormalities. Complex ultrasound abnormalities, in particular, hold greater clinical significance. This study demonstrates the utility of CMA for detecting chromosomal abnormalities in first-trimester CVS. Our findings support the integration of CMA into early prenatal diagnostic protocols.

2025-12-04 | GSE306863 | GEO

Can non-invasive prenatal screening based on cell-free fetal DNA be utilized to assess chromosome abnormalities in fetuses with increased Nuchal Translucency?

Project description:Objective: The study compared the incidence of aneuploidy and copy number variations (CNVs) in fetuses with increased nuchal translucency (NT) to those with clear indications for non-invasive prenatal screening (NIPS), aiming to evaluate the risk of routine aneuploidy (RA) and pathogenic submicroscopic abnormalities and the potential use of NIPS for fetuses with increased NT. Methods: The study retrospectively analyzed 716 pregnant women with isolated increased NT in Group IiNT and 2960 pregnant women in the control group. The control group was divided into sub-Group A (1531 patients underwent invasive prenatal diagnosis for advanced maternal age (AMA)), sub-Group B (1331 for high-risk maternal serum screening (hMSS)), and sub-Group C (98 for both hMSS and AMA). All cases underwent karyotyping and chromosomal microarray analysis. Results: In Group IiNT and each sub-group, there were cases of RA (17, 28, 24, and 1) and clinically significant CNVs (22, 19, 39, and 5), respectively. There was no significant difference in RA incidence between Group IiNT and the control group/subgroups. Similarly, there was no statistical difference in clinically significant CNVs and CNVs <10 Mb between Group IiNT and sub-Group B/C or the control group. Only Group IiNT and sub-Group A showed a significant difference. Conclusion: Using NIPS with broader and deeper sequencing could theoretically potentially serve as a screening tool for identifying global chromosomal and submicroscopic abnormalities in fetuses with isolated increased NT. However, further research is required to determine the clinical application and to assess the efficacy of NIPS in detecting abnormalities. Traditional karyotyping and SNP array was performed on all 3676 pregnancies.

2023-04-30 | GSE230763 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data